Previous Close | 1.7850 |
Open | 1.9950 |
Bid | 1.8300 x 0 |
Ask | 1.9500 x 0 |
Day's Range | 1.6450 - 1.9950 |
52 Week Range | 0.7920 - 4.9600 |
Volume | |
Avg. Volume | 38,313 |
Market Cap | 35.829M |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6300 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.